cco独立economic evaluation addition carfilzomib to lenalidomide dexamethasone cost effective for mmCarfilzomib到Lenalidomide对成本效益.pptx

CCOIndependentConferenceCoverage*

ofthe2016ASCOAnnualMeeting,June3-7,2016EconomicEvaluation:AdditionofCarfilzomibtoLenalidomide/

DexamethasoneCostEffectiveforR/RMM*CCOisanindependentmedicaleducationcompanythatprovidesstate-of-the-artmedicalinformationtohealthcareprofessionalsthroughconferencecoverageandothereducationalprograms.ThisactivityissupportedbyeducationalgrantsfromAmgen,Ariad,

BayerHealthcarePharmaceuticals,CelgeneCorporation,Genentech,Incyte,Merck,andTaihoPharmaceuticals.

CarfilzomibEconomicEvaluation:BackgroundPhaseIIIASPIREtrial:KRdproducedsuperiorPFSandimprovedQoLvsRdinrelapsed/refractoryMM[1]MedianPFS:26.3vs17.6mos(HR:0.69;P=.0001)Currentstudyassessedcost-effectivenessofKRdvsRdfromaUSpayerperspective[2]DatafromASPIREsupplementedwithlong-termOSdatafromSEER1.StewartAK,etal.NEnglJMed.2015;372(2):142-152.

2.JakubowiakAJ,etal.ASCO2016.Abstract8021.Slidecredit:

CarfilzomibEconomicEvaluation:

StudyDesignPartitionedsurvivalmodelbuiltwith30-yrhorizon,with3typesofpts(basedones):progression-free,postprogression,deathTreatmenteffectforPFSandOSestimatedwithparametricregressionmodelsadjustedforptbaselinecharacteristicsinASPIREandappliedovertimehorizonOSdatainASPIREimmature;OSdatafromSEERmatchedtoASPIREptsonsex,age,timesincediagnosis,andextrapolatedforOScurvebeyondASPIREdatabasedonHRofKRdvsRdOScurveGrade≥3AEswith2%incidenceinanyASPIREarmincludedUtilitiesderivedfromliteratureandadjustedforrelativeimprovementinQoLincreaseobservedwhenptswereprogression-freeinASPIRESurvivalanalysisconductedaccordingtoNICEguidelinesJakubowiakAJ,etal.ASCO2016.Abstract8021.Slidecredit:

CarfilzomibEconomicEvaluation:

StudyDesignDrugcostsbasedonWACpricesRegimencostcalculationsincluded:averagedoseperadministration,numberof